Caribou Biosciences (CRBU) Capital Expenditures (2020 - 2025)

Caribou Biosciences (CRBU) has 6 years of Capital Expenditures data on file, last reported at -$216000.0 in Q4 2025.

• Capital Expenditures for Q4 2025 came in at -$216000.0, down 156.69% year-over-year; the trailing twelve-month figure through Mar 2026 was $1.2 million (up 6811.11% YoY), and the FY2025 annual result was $1.4 million, up 80.24% from the prior year.
• Capital Expenditures eased to -$216000.0 in Q4 2025 per CRBU's latest filing, from $115000.0 in the prior quarter.
• Over five years, Capital Expenditures peaked at $4.0 million in Q3 2022 and troughed at -$4.0 million in Q3 2023.
• A 5-year average of $307450.0 and a median of $289500.0 in 2024 frame the typical range for Capital Expenditures.
• The sharpest annual moves came in 2021 and 2022: Capital Expenditures jumped 6542.86% in 2021, then slumped 607.15% in 2022.
• A 5-year view of Capital Expenditures shows it stood at $685000.0 in 2021, then tumbled by 607.15% to -$3.5 million in 2022, then jumped by 103.91% to $136000.0 in 2023, then surged by 180.15% to $381000.0 in 2024, then sank by 156.69% to -$216000.0 in 2025.
• Business Quant data shows CRBU's Capital Expenditures at -$216000.0 in Q4 2025, $115000.0 in Q3 2025, and $1.3 million in Q2 2025.